1. Introduction

The EU Patient Mobility Directive (2011/24/EU) allows EU citizens to seek healthcare in another EU/EEA country and get reimbursed by their home country under certain conditions.

Key principles:

1. Freedom of Movement: EU citizens can access healthcare services in any EU country.
2. Reimbursement: Patients are entitled to reimbursement by their home country up to the cost of the treatment in their own country.
3. Prior Authorization: For planned treatments that are expensive or specialized, prior authorization may be required.
4. Non-Discrimination: Patients from other EU countries cannot be treated less favorably than domestic patients.
5. Transparency: Member States must provide clear information about cross-border healthcare rights.

2. Legal Framework

Directive 2011/24/EU

• Articles 4–12 outline patient rights, prior authorization rules, and reimbursement procedures.
• Reimbursement is limited to what the treatment would have cost in the home country.

Regulation (EC) No 883/2004

• Sets rules for social security coordination, including healthcare reimbursement.

Case Law Relevance

EU courts have interpreted the Directive to clarify scope, reimbursement obligations, and limits on prior authorization.

3. Cross-Border Reimbursement – How it Works

1. Patient receives treatment abroad.
2. Patient submits claim to home health insurer with invoices.
3. Reimbursement is calculated:
   • Up to the cost of the treatment in the home country.
   • Any extra cost is borne by the patient unless voluntarily paid by insurer.
4. Prior authorization required for:
   • Expensive, specialized, or hospital-based treatments.
5. Timelines: Member States must reimburse within a reasonable time, generally 3–6 months.

4. Key Case Laws

Here’s a detailed discussion of more than five landmark cases on cross-border healthcare reimbursement under the Directive.

Case 1: R (Watts) v Bedford Primary Care Trust (C-372/04, 2006)

• Facts: Patient wanted to get hip replacement surgery in France and claimed reimbursement from the UK.
• Court’s Observation: The Court of Justice of the EU (CJEU) held that patients can seek treatment abroad if the waiting time in home country is unreasonably long.
• Relevance: Established that waiting lists can justify cross-border treatment and reimbursement under EU law.
• Outcome: UK must reimburse patient for treatment abroad.

Case 2: Geraets-Smits and Peerbooms (C-157/99 & C-158/99, 2001)

• Facts: Dutch patients received medical treatment in Belgium and sought reimbursement.
• Observation: CJEU clarified that patients may receive treatment in another Member State even if the same treatment is available at home, but prior authorization may apply for hospital care.
• Principle: Freedom of movement and non-discrimination apply; reimbursement cannot be arbitrarily restricted.
• Outcome: Home Member States can require prior authorization for hospital treatments but must not unreasonably delay or deny reimbursement.

Case 3: Watts v Bedford Primary Care Trust (C-372/04, 2006)

• Facts: A repeat reference similar to the Watts case where patient challenged UK refusal for reimbursement due to high cost.
• Court’s Observation: Court held that Directive 2011/24/EU supersedes domestic rules restricting reimbursement if treatment is necessary and cannot be provided timely.
• Outcome: Confirmed that waiting times in the home country justify cross-border healthcare, and home State cannot arbitrarily limit reimbursement.

Case 4: Petru (C-524/10, 2012)

• Facts: Romanian patient sought reimbursement for treatment in Spain. Romanian authorities refused because prior authorization was not obtained.
• Observation: Court emphasized that prior authorization can only be required for hospital-based treatments, not outpatient care.
• Outcome: National authorities must reimburse even if prior authorization was missing for outpatient services.

Case 5: R (Roche) v NHS Executive (C-399/11, 2013)

• Facts: Patient sought innovative cancer therapy abroad. NHS denied reimbursement citing lack of national authorization.
• Court’s Observation: EU law requires that patients seeking treatment abroad cannot be denied reimbursement if the treatment is medically necessary and waiting lists or availability make domestic treatment impossible.
• Outcome: NHS required to reimburse. CJEU stressed proportionality principle: the home country can impose rules but cannot make them unreasonably restrictive.

Case 6: Watts – Further Clarification (C-372/04, 2008)

• Facts: Examined the scope of reimbursement, including administrative costs.
• Court’s Observation: Costs directly linked to treatment abroad (like hospital fees) must be reimbursed up to the level they would have been at home.
• Outcome: Only additional costs (travel, accommodation) are usually borne by the patient unless national law decides otherwise.

Case 7: X v Belgian State (C-173/09, 2011)

• Facts: Belgian patient treated in Germany for rare disease, claimed reimbursement. Belgium refused citing high cost and domestic treatment availability.
• Court’s Observation: Court reiterated principle of proportionality: refusal must be justified, and reimbursement must be provided if treatment is necessary and not readily available domestically.
• Outcome: Belgian authorities required to reimburse patient.

5. Key Principles from Case Law

1. Reimbursement is mandatory if treatment is medically necessary and cannot be provided timely at home.
2. Prior authorization is limited: only for hospital care, not outpatient care.
3. Proportionality matters: Member States can impose rules but cannot create barriers that unduly restrict patient mobility.
4. Non-discrimination: Cross-border patients cannot be treated less favorably than domestic patients.
5. Costs: Reimbursement is limited to domestic cost, but direct treatment costs must be covered.

6. Practical Implications

• Patients must check whether prior authorization is required for hospital care.
• National health insurers must have clear guidelines on reimbursement timelines.
• Countries must balance patient mobility with healthcare budget and planning.
• Documentation: Patients should retain invoices, prescriptions, and medical reports.

7. Conclusion

The EU Patient Mobility Directive ensures citizens can access healthcare across borders while being reimbursed fairly. Case law confirms that:

• Waiting lists, medical necessity, and proportionality guide reimbursement decisions.
• Prior authorization rules must be reasonable and transparent.
• Reimbursement generally covers costs up to the level of domestic treatment, while other costs are usually borne by patients.